Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical

See also
Status	Clinical Trial	Phase
Completed	`NCT00978380` - Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725	Phase 3
Completed	`NCT02568202` - Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)	N/A
Completed	`NCT01949792` - A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors	Phase 1
Completed	`NCT01205724` - Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A	Phase 1
Completed	`NCT01562587` - Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State	Phase 1
Completed	`NCT00108797` - Trial of NovoSeven® in Haemophilia - Joint Bleeds	Phase 4
Completed	`NCT01493778` - Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A	Phase 3
Completed	`NCT02490787` - Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects	Phase 1
Completed	`NCT00951405` - Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors	Phase 2
Completed	`NCT01876745` - A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan	N/A
Completed	`NCT02920398` - A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A	Phase 1
Completed	`NCT00984126` - Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015	Phase 3
Completed	`NCT01228669` - Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B	Phase 1
Completed	`NCT01988532` - Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia	N/A
Completed	`NCT01234545` - Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors	N/A
Completed	`NCT01779921` - Treatment of Congenital Factor VII Deficiency	N/A
Completed	`NCT01563471` - Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers	Phase 1
Completed	`NCT02941354` - Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A	Phase 1
Completed	`NCT02241694` - To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives	N/A
Completed	`NCT01230021` - Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency	Phase 3

NCT number	NCT01489111
Study type	Interventional
Source	Novo Nordisk A/S
Contact
Status	Completed
Phase	Phase 3
Start date	August 3, 2012
Completion date	December 10, 2018

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. — pathfinder™3

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms